Reuters logo
BRIEF-Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline
October 6, 2017 / 12:26 PM / in 12 days

BRIEF-Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline

Oct 6 (Reuters) - Paratek Pharmaceuticals Inc

* Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline in patients with difficult to treat comorbid conditions

* Paratek - ‍in mITT analysis population, omadacycline achieved primary efficacy endpoint of statistical non-inferiority versus linezolid​

* Paratek pharmaceuticals - ‍omadacycline was safe and generally well tolerated in patients with chronic kidney disease​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below